tradingkey.logo
搜索

Nexalin Technology Inc

NXL
添加自选
0.361USD
-0.019-5.00%
收盘 07/02, 13:00美东报价延迟15分钟
7.43M总市值
亏损市盈率 TTM

Nexalin Technology Inc

0.361
-0.019-5.00%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-5.00%

5天

+1.69%

1月

-33.14%

6月

-43.59%

今年开始到现在

-35.30%

1年

-62.40%

关键数据
0.396今开
0.400最高
108.06K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.53%换手率
0.380昨收
0.361最低
29.19K成交额
亏损市盈率静
2.57市净率
0.00%股息率 TTM
-252.65%ROA
2.00052周最高
0.80量比
-7.61M净利润
20.58M总股本
-0.4580每股收益TTM
3.76Beta
-319.69%ROE
0.30552周最低
10.26%振幅
87.85%毛利率
7.43M总市值
-4.74回报/风险
6.25%风险率

TradingKey Nexalin Technology Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

Nexalin Technology Inc当前公司基本面数据相对非常健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名129/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价2.00。中期看,股价处于平稳状态。近一个月,市场表现非常差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Nexalin Technology Inc评分

相关信息

行业排名
129 / 204
全市场排名
309 / 4565
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Nexalin Technology Inc亮点

亮点风险
Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
业绩高增长
公司营业收入稳步增长,连续3年增长172.37%
业绩增长期
公司处于发展阶段,最新年度总收入301.65K美元
利润高增长
公司净利润处于行业前列,最新年度总收入301.65K美元
估值高估
公司最新PE估值-0.79,处于3年历史高位
机构加仓
最新机构持股1.43M股,环比增加26.88%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值6.65K
活跃度降低
近期活跃度降低,过去20天平均换手率-0.77

分析师目标

根据 1 位分析师
买入
评级
2.000
目标均价
+426.32%
涨幅空间

Nexalin Technology Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Nexalin Technology Inc简介

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety, depression and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It has also designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
公司代码NXL
公司Nexalin Technology Inc
CEOWhite (Mark)
网址https://nexalin.com

常见问题

Nexalin Technology Inc(NXL)的当前股价是多少?

Nexalin Technology Inc(NXL)的当前股价是 0.36。

Nexalin Technology Inc的股票代码是什么?

Nexalin Technology Inc的股票代码是NXL。

Nexalin Technology Inc股票的52周最高点是多少?

Nexalin Technology Inc股票的52周最高点是2.00。

Nexalin Technology Inc股票的52周最低点是多少?

Nexalin Technology Inc股票的52周最低点是0.30。

Nexalin Technology Inc的市值是多少?

Nexalin Technology Inc的市值是6.57M。

现在Nexalin Technology Inc(NXL)的股票是买入、持有还是卖出?

根据分析师评级,Nexalin Technology Inc(NXL)的总体评级为买入,目标价格为2.00。

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是多少

Nexalin Technology Inc(NXL)股票的每股收益(EPS TTM)是-0.50。